摘要
目的探讨长春西汀治疗慢性脑供血不足的临床疗效及安全性,总结临床经验以提高治疗及用药水平。方法将2014-01—2015-08我科收治的140例慢性脑供血不足患者随机分成对照组和观察组,其中对照组患者采用复方丹参注射液治疗,观察组给予长春西汀治疗,记录相关临床资料并进行回顾性分析。结果治疗后观察组的LVA、RVA、BA血流速度大于对照组,差异具有统计学意义(P<0.05);观察组总有效率优于对照组,差异具有统计学意义(P<0.05);治疗期间2组均未发生明显不良反应。结论长春西汀治疗慢性脑供血不足的临床疗效明显,安全性良好,能够明显改善LVA、RVA及BA的血流速度,值得临床推广。
Objective To explore the clinical effect and safety of vinpocetine for the treatment of the chronic cerebral circulation insufficiency (CCCI) and summarize the clinical experiences to improve the level of treatment and medication. Methods Totally 140 cases suffering from the chronic cerebral circulation insufficiency admitted in our department from January 2014 to August 2015 were randomly divided into control group treated by compound danshen injection and observation group treated by vinpocetine. Then we recorded the related clinical data which were retrospectively analyzed. Results After treatment, the blood flow velocities of LVA, RVA, BA in the observation group were greater than those in the control group, and the differences were statistically significant (P〈0.05). The observation group had higher total effective rate than the control group, with a significant difference (P〈0.05). No obvious adverse reactions in both two groups were found. Conclusion Vinpocetine in the treatment of chronic cerebral circulation insufficiency is effective and safe, which can obviously improve the blood flow velocity of LVA, RVA and BA of. We should strenethen clinical researches and further make it ponular.
出处
《中国实用神经疾病杂志》
2016年第14期20-21,共2页
Chinese Journal of Practical Nervous Diseases
关键词
慢性脑供血不足
长春西汀
安全性
Chronic cerebral circulation insufficiency
Vinpocetine
Security